aod9604 fda approved AOD-9604 5mg (Spray) – Modified Aminos Peptides for Weight Loss Explained:

What This Means Clinically For patients who have tried GLP-1 medications and experienced significant side effects, or who are not candidates for appetite-suppressing approaches, AOD 9604 represents a mechanistically different option

Up to 60% of people have a version of this mutation leading to a decreased ability to absorb B12

Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health

The standard research protocol is 300 mcg per day, subcutaneous, administered in a fasted state, typically in the morning before food or exercise

These patients may experience a blunted or impeded response to the intranasal medication